<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03834688</url>
  </required_header>
  <id_info>
    <org_study_id>PrE0405</org_study_id>
    <secondary_id>ML40551</secondary_id>
    <nct_id>NCT03834688</nct_id>
  </id_info>
  <brief_title>Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age</brief_title>
  <acronym>PrE0405</acronym>
  <official_title>Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PrECOG, LLC.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PrECOG, LLC.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible untreated patients will receive single arm venetoclax, bendamustine and rituximab as&#xD;
      induction therapy. After 6 cycles, maintenance rituximab may be administered per physician&#xD;
      discretion.&#xD;
&#xD;
      Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2&#xD;
      (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with&#xD;
      mantle cell lymphoma. Venetoclax may make the cancer cells sensitive to chemotherapy. This&#xD;
      may help to slow down the growth of cancer or may cause cancer cells to die.&#xD;
&#xD;
      The purpose of this study is to see if venetoclax in combination with bendamustine and&#xD;
      rituximab chemotherapy is effective in treating people who have mantle cell lymphoma and to&#xD;
      examine the side effects, good and bad, associated with this combination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mantle cell lymphoma (MCL) is a subtype of Non-Hodgkin Lymphoma (NHL) which is considered&#xD;
      incurable with conventional therapy. With an incidence of approximately 70,000 cases&#xD;
      diagnosed in the United States (US) per year, the disease is rare.&#xD;
&#xD;
      This is an open-label phase II study of venetoclax in combination with bendamustine and&#xD;
      rituximab. Patients will receive induction therapy with venetoclax, bendamustine and&#xD;
      rituximab for six cycles (1 cycle = 28 days). There will be an interim analysis after 19&#xD;
      patients are enrolled to evaluate for tumor lysis syndrome (TLS). TLS is caused by the fast&#xD;
      breakdown of cancer cells which can lead to electrolyte and kidney problems.&#xD;
&#xD;
      Tumor assessments will be performed after Cycle 3-4 and at end of induction therapy.&#xD;
&#xD;
      Mandatory pre-treatment tumor tissue sample (i.e., obtained in the course of standard biopsy&#xD;
      or surgery) will be required for research (if sufficient tissue is available).&#xD;
&#xD;
      Mandatory bone marrow aspirate (obtained in the course of standard biopsy) and peripheral&#xD;
      blood sample will be collected at the end of treatment for Minimal Residual Disease (MRD).&#xD;
      MRD measures the disease remaining after treatment. Optional peripheral blood samples will&#xD;
      also be collected for future research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2020</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-Label, Single-Arm Study, Cycle 1 Dose Escalation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response (CR) rate at end of induction</measure>
    <time_frame>30 months</time_frame>
    <description>CR assessed in accordance with Lymphoma Response Criteria (Cheson Criteria)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>60 months</time_frame>
    <description>Number of participants with abnormal laboratory values and/or adverse events with particular attention to TLS related to treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>60 months</time_frame>
    <description>ORR assessed in accordance with Lymphoma Response Criteria (Cheson Criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>60 months</time_frame>
    <description>PFS assessed in accordance with Lymphoma Response Criteria (Cheson Criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>60 months</time_frame>
    <description>OS assessed in accordance with Lymphoma Response Criteria (Cheson Criteria)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Induction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Venetoclax, bendamustine and rituximab as induction therapy for 6 cycles of 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Cycle 1: Venetoclax by mouth daily. The dose will gradually increase during Cycle 1. (Day 1-7: 20 mg; Day 8-14: 50 mg; Day 15-21: 100 mg; Day 22-28: 200 mg.)&#xD;
Cycles 2-6: Venetoclax 400 mg by mouth daily on Days 1-10 (1 cycle = 28 days).</description>
    <arm_group_label>Induction</arm_group_label>
    <other_name>GDC-0199</other_name>
    <other_name>ABT-199</other_name>
    <other_name>RO5537382</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Cycle 1-6: Bendamustine 90 mg/m² intravenous (IV) on Days 1 and 2 of each cycle. Bendamustine may be started at 70 mg/m² in patients over the age of 75 years with comorbid conditions or patients over the age of 80 years without comorbid conditions.</description>
    <arm_group_label>Induction</arm_group_label>
    <other_name>Bendamustine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Cycle 1-6: Rituximab 375 mg/m² IV on Day 1 of each cycle. After 2 consecutive cycles of Rituximab IV are well tolerated, Rituximab may be given subcutaneously.</description>
    <arm_group_label>Induction</arm_group_label>
    <other_name>Chimeric anti-CD20 monoclonal antibody</other_name>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed (biopsy-proven) diagnosis of mantle cell&#xD;
             lymphoma (MCL), with documented cyclin D1 (BCL1) expression by immunohistochemical&#xD;
             stains and/or t(11;14) by cytogenetics or FISH.&#xD;
&#xD;
          -  Patients must have measurable or evaluable disease as defined as a lymph node&#xD;
             measuring &gt;1.5 cm in any dimension or splenomegaly with spleen &gt;15 cm in craniocaudal&#xD;
             dimension.&#xD;
&#xD;
          -  Age ≥ 60 years.&#xD;
&#xD;
          -  No intention to undergo consolidation with high dose chemotherapy and autologous stem&#xD;
             cell rescue (Autologous Stem Cell Transplant) in first remission.&#xD;
&#xD;
          -  ECOG performance status of 0-2.&#xD;
&#xD;
          -  Ability to understand and willingness to sign Institutional Review Board&#xD;
             (IRB)-approved informed consent.&#xD;
&#xD;
          -  Willing to provide mandatory tissue samples (if sufficient tissue available), bone&#xD;
             marrow and blood samples for research purposes.&#xD;
&#xD;
          -  Adequate organ function as measured by the following criteria, obtained ≤ 2 weeks&#xD;
             prior to registration:&#xD;
&#xD;
               -  Absolute Neutrophil Count (ANC) ≥ 1000/mm³&#xD;
&#xD;
               -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
               -  Platelets ˃75,000/mm³&#xD;
&#xD;
               -  Creatinine clearance ≥ 40 mL/min, calculated with the use of 24-hour creatinine&#xD;
                  clearance or by Cockcroft-Gault formula&#xD;
&#xD;
               -  Total Bilirubin ≤ 1.5x Upper Limit of Normal (ULN) or ≤ 3x ULN for patients with&#xD;
                  documented Gilbert's syndrome&#xD;
&#xD;
               -  Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) ≤ 2.5x ULN&#xD;
&#xD;
          -  All females of childbearing potential (not surgically sterilized and between menarche&#xD;
             and 1 year post menopause) must have a blood test to rule out pregnancy within 2 weeks&#xD;
             prior to registration.&#xD;
&#xD;
          -  Women must not be pregnant or breastfeeding. Females of childbearing potential who are&#xD;
             sexually active with a non-sterilized male partner and sexually active men must agree&#xD;
             to use 2 methods of adequate contraception (hormonal plus barrier or 2 barrier forms)&#xD;
             prior to study entry, for the duration of study participation, and for 12 months after&#xD;
             last dose of therapy. Method of contraception must be documented.&#xD;
&#xD;
          -  Patients should not have prior chemotherapy, radiotherapy or immunotherapy for&#xD;
             lymphoma.&#xD;
&#xD;
          -  Patients must have no recent (&lt;1 year) history of malignancy except for the following:&#xD;
&#xD;
               -  adequately treated non-melanoma skin cancer&#xD;
&#xD;
               -  adequately treated Stage I melanoma of the skin&#xD;
&#xD;
               -  in situ cervical cancer&#xD;
&#xD;
               -  low grade prostate adenocarcinoma (Gleason grade ≤ 6) managed with observation&#xD;
                  and stable for 6 months.&#xD;
&#xD;
          -  Patients should not have known evidence of central nervous system (CNS) lymphoma.&#xD;
&#xD;
          -  Patients must not have received a prior allogeneic stem cell transplant or solid organ&#xD;
             transplant (except for cornea) for any indication.&#xD;
&#xD;
          -  Patients must have no active, uncontrolled infections.&#xD;
&#xD;
          -  Patients must not have active hepatitis B or be chronic carriers of hepatitis B. This&#xD;
             is defined as patients with hepatitis B surface antigen (HBsAg) positive. Patients&#xD;
             with prior exposure to hepatitis B (hepatitis B core antibody (anti-HBc) positive AND&#xD;
             HBsAg negative) are allowed with a protective level hepatitis B surface antibody AND a&#xD;
             negative hepatitis B viral load by polymerase-chain reaction (PCR).&#xD;
&#xD;
          -  Patients must not have active hepatitis C (HCV) as defined by a hepatitis C viral load&#xD;
             detectable by PCR. Patients with a negative HCV antibody are assumed to have a&#xD;
             negative HCV viral load. Patients with a positive HCV antibody must have a negative&#xD;
             hepatitis C viral load by PCR. Prior treatment for an active HCV infection will be&#xD;
             allowed as long as the hepatitis C viral load by PCR is negative.&#xD;
&#xD;
          -  Patients must not have known active Human Immunodeficiency Virus (HIV). Testing not&#xD;
             required in absence of clinical suspicion.&#xD;
&#xD;
          -  Patients must not have evidence of significant, uncontrolled concomitant diseases,&#xD;
             including psychiatric diseases, that could affect compliance with the protocol or&#xD;
             interpretation of results or that could increase risk to the patient.&#xD;
&#xD;
          -  Patients must not have conditions that preclude oral administration or absorption of&#xD;
             medications through the GI tract, including but not limited to the inability to&#xD;
             swallow pills or malabsorption syndromes.&#xD;
&#xD;
          -  Patients must not have known allergies to both xanthine oxidase inhibitors and&#xD;
             rasburicase.&#xD;
&#xD;
          -  Patients must not require the use of warfarin. Blood thinners of other classes are&#xD;
             permitted.&#xD;
&#xD;
          -  Patient may not receive the following agents within 7 days prior to the first dose of&#xD;
             venetoclax:&#xD;
&#xD;
               -  Strong and moderate CYP3A inhibitors&#xD;
&#xD;
               -  Strong and moderate CYP3A inducers&#xD;
&#xD;
               -  Strong and moderate P-gp inhibitors&#xD;
&#xD;
          -  Patients must not have consumed grapefruit, grapefruit products, Seville oranges&#xD;
             (including marmalade containing Seville oranges), or star fruit within 3 days prior to&#xD;
             the first dose of venetoclax.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig Portell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carolyn Andrews, RN</last_name>
    <phone>267-207-4070</phone>
    <email>PrE0405@precogllc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Mbuvi</last_name>
      <phone>217-383-4085</phone>
      <email>pauline.mbuvi@carle.com</email>
    </contact>
    <investigator>
      <last_name>Priyank Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Weisenbach</last_name>
      <phone>317-278-0597</phone>
      <email>jweisenb@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Robertson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherri Miller</last_name>
      <phone>913-574-0266</phone>
      <email>smiller15@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Hoffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Mercy Hospital Cancer Care Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kellie Miller</last_name>
      <phone>734-712-6651</phone>
      <email>kellie.n.miller@stjoeshealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher M. Reynolds, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Elert</last_name>
      <phone>507-538-3227</phone>
      <email>elert.kathleen@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Nabila (Nora) Bennani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chapelle Ayres</last_name>
      <phone>314-388-6506</phone>
      <email>ayreschapelle@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Brad Kahl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dama Bhavsar</last_name>
      <phone>732-235-6008</phone>
      <email>bhavsadm@cinj.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin David, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Cancer Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Rizzo</last_name>
      <phone>717-531-0003</phone>
      <phone_ext>289630</phone_ext>
      <email>krizzo@pennstatehealth.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Seema Naik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Reading Hospital/McGlinn Cancer Institute</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Miller</last_name>
      <phone>484-628-8549</phone>
      <email>barbara.miller@towerhealth.org</email>
    </contact>
    <investigator>
      <last_name>Terrence Cescon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Stallard</last_name>
      <phone>434-243-2649</phone>
      <email>elg9r@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Portell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gundersen Health System</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlin Chambers</last_name>
      <phone>608-775-1826</phone>
      <email>krchambe@gundersenhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kurt Oetell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 6, 2019</study_first_submitted>
  <study_first_submitted_qc>February 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2019</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Venetoclax</keyword>
  <keyword>Bendamustine</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Bcl-2 Family Protein Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data is proprietary</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

